Search
Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreDaratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read moreImmunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreStopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read moreEHA Award winners put in the spotlight in Copenhagen
The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.
Read morePRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read moreSurvey Monitoring H2020 – your input is needed!
We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.
Read more